ArticleMolecular biology reports2026
IGFL2-AS1 is associated with poor prognosis in cervical cancer and promotes disease progression via the miR-126-5p/MACC1 axis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCervical cancer (CC) is a common malignancy. And long non-coding RNAs (lncRNAs) have been identified as pivotal molecular modulators in tumorigenesis, with particular relevance to cervical carcinoma pathogenesis.
aimThis study sought to examine the expression, biological functions, and mechanisms of IGFL2-AS1 in CC, and to evaluate its association with clinical prognosis.
methodsThe present investigation examined IGFL2-AS1 expression levels in paired tumor and paracancerous normal specimens obtained from a cohort of 131 CC cases. Next, the biological functions of IGFL2-AS1 were evaluated in CC cells through proliferation, migration, and invasion assays. Mechanistic studies were conducted using bioinformatics prediction, dual-luciferase reporter assays, and functional experiments (CCK-8 proliferation assays, Transwell migration and invasion assays, and RT-qPCR) to elucidate the IGFL2-AS1/miR-126-5p/MACC1 axis.
resultsElevated expression of IGFL2-AS1 was observed in CC tissues, showing significant correlations with disease progression (large tumor size, advanced International Federation of Gynecology and Obstetrics (FIGO) stage, and lymph node metastasis) and unfavorable clinical prognosis. Functional analyses revealed that it promoted CC cell proliferation, migration, invasion, and stemness maintenance. Mechanistically, IGFL2-AS1 acted as a ceRNA to sponge miR-126-5p, consequently relieving its suppression of MACC1. The IGFL2-AS1/miR-126-5p/MACC1 axis was shown to drive the malignant phenotype of CC cells.
conclusionsIGFL2-AS1 is upregulated in CC and correlates with poor prognosis. Mechanistically, it promotes malignant phenotypes in CC cells via the miR-126-5p/MACC1 axis.
Indexed as
Identifiers
42319601What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.